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Abstract
Purpose: In ongoing clinical research on metastatic castration-
resistant prostate cancer (mCRPC) treatment, the potential
enhanced efﬁcacy of the combination of taxanes with AR-targeted
agents, that is, enzalutamide and abiraterone, is currently being
explored. Because enzalutamide induces the CYP3A4 enzyme and
taxanes are metabolized by this enzyme, a potential drug–drug
interaction needs to be investigated.
Experimental Design: Therefore, we performed a pharmaco-
kinetic cross-over study in mCRPC patients who were sched-
uled for treatment with cabazitaxel Q3W (25 mg/m2). Patients
were studied for three consecutive cabazitaxel cycles. Enzalu-
tamide (160 mg once daily) was administered concomitantly
after the ﬁrst cabazitaxel cycle, during 6 weeks. Primary end-
point was the difference in mean area under the curve (AUC)
between the ﬁrst (cabazitaxel monotherapy) and third cabazi-
taxel cycle, when enzalutamide was added.
Results:Apotential clinically relevant 22% (95%CI, 9%–34%;
P ¼ 0.005) reduction in cabazitaxel exposure was found with
concomitant enzalutamide use. The geometric mean AUC0–24h of
cabazitaxel was 181 ngh/mL (95% CI, 150–219 ngh/mL) in
cycle 3 and 234 ngh/mL (95% CI, 209–261 ngh/mL) in cycle 1.
This combination did not result in excessive toxicity, whereas PSA
response was promising.
Conclusions: We found a signiﬁcant decrease in cabazitaxel
exposure when combined with enzalutamide. In an era of
clinical trials on combination strategies for mCRPC, it is
important to be aware of clinically relevant drug–drug inter-
actions. Because recent study results support the use of a lower
standard cabazitaxel dose of 20 mg/m2, the clinical relevance of
this interaction may be substantial, because the addition of
enzalutamide may result in subtherapeutic cabazitaxel expo-
sure. Clin Cancer Res; 24(3); 541–6. 2017 AACR.
Introduction
The current treatment paradigm in mCRPC comprises mono-
therapy options with chemotherapy, that is, docetaxel or cabazi-
taxel, or with novel hormonal therapies, including enzalutamide
andabiraterone (1).Clinical studieswith various combinationsof
therapies, for example, taxanes with novel hormonal therapies,
with various designs and aims, are in progress (e.g., https://
clinicaltrials.gov/ct2/show/NCT02522715; refs. 2–5). A summary
of ongoing clinical trials on these combinations was recently
reviewed by Sternberg, and showed the rationale for combination
therapies (6). In addition, preclinical in vivo work has shown that
the activity of cabazitaxel is strongly affected by hormonalmanip-
ulations, for example, either by castration or testosterone supple-
mentation (7). Clinical studies with combined treatments,
although, warrant thorough pharmacokinetic investigation to test
for clinical relevant drug–drug interactions.
Taxanes, that is, docetaxel and cabazitaxel, have an extensive
hepatic metabolism (63–77%) and biliary excretion (8). Their
metabolism is mediated by CYP3A iso-enzymes in the liver, and
for a small part by CYP2C8. Therefore, liver (dys-)function is a
major factor in taxane dose adaptations (9). Pharmacokinetics of
docetaxel show a considerable interpatient variability (30–50%),
depending on patient characteristics, like gender and age. The
interpatient variability of cabazitaxel is moderate (~24%) and
cabazitaxel pharmacokinetics are less susceptible for patient char-
acteristics (10). However, the use of co-medication and herbal
supplements, especially (strong) inducers/inhibitors of the
CYP3A-system inﬂuence the pharmacokinetics of all taxanes
(11–13). The inﬂuence of CYP3A-inducers on the pharmacoki-
netics of cabazitaxel have been extensively investigated by Sar-
antopoulos and colleagues, showing that cabazitaxel is suscepti-
ble for CYP3A induction or inhibition. Repeated administration
of a strong CYP3A inducer, rifampin, resulted in an 21% increase
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in cabazitaxel clearance and a 17% decrease in cabazitaxel con-
centration (14). Additionally, the pharmacokinetics of taxanes
can potentially be inﬂuenced by changes in drug transporters, like
ABCB1 (P-glycoprotein; refs. 11, 15). Although cabazitaxel has
less propensity for ABCB1 mediated drug resistance, the upregu-
lation of the efﬂux pump can potentially impact the pharmaco-
kinetics of cabazitaxel (16).
Enzalutamide is known to be a moderate inducer of CYP2C9
and CYP2C19 and a strong inducer of CYP3A4.Maximal CYP3A4
induction by enzalutamidemay not appear until onemonth after
treatment start, when steady-state levels of enzalutamide are
reached (17). Because enzalutamide induces CYP3A4, and
because taxanes are predominantly metabolized via that enzyme,
a drug–drug interaction between these agents is expected (12, 15).
Recently, Morris and colleagues published a pharmacokinet-
ic study in patients on the combination of enzalutamide and
docetaxel (18). They found a 12% decrease in docetaxel con-
centrations during concomitant enzalutamide use compared
with docetaxel alone, which they regarded as clinically irrele-
vant. However, given the short combination period of only 3
weeks, during which steady state exposure of enzalutamide may
not have been reached yet, the true drug–drug interaction might
be larger than reported. The half-life and steady-state level of
orally administrated enzalutamide (160 mg once daily) are
relatively long: 6 days and 4 weeks, respectively. So, to identify
the true inductive effects of enzalutamide on cabazitaxel expo-
sure, we aimed to study the combination for at least the time-
period that steady state of enzalutamide (i.e., after 4 weeks) is
reached (17). Therefore, we studied 3 consecutive cabazitaxel
cycles in our trial, where enzalutamide is used for 6 weeks by
men with mCRPC.
Patients and Methods
Between April 2015 and August 2016 this prospective, non-
randomized, nonblinded, cross-over, pharmacokinetic trial was
undertaken in the Erasmus University Medical Center in Rotter-
dam, the Netherlands. The Ethical board of the Erasmus Univer-
sity Medical Center approved the study protocol and written
informed consent was obtained from all participants. The study
was conducted in accordance with the ethical guidelines of the
Declaration of Helsinki. The study was registered at the Dutch
Trial Register (www.trialregister.nl) by number NTR5164.
Study population
Patients enrolled in this study had histologically proven ade-
nocarcinoma of the prostate with documented progression after
docetaxel treatment and were eligible to receive second line
chemotherapy, that is, cabazitaxel. As the pharmacokinetic inter-
action was our primary endpoint, prior cabazitaxel treatment was
allowed and prior enzalutamide treatment had to be ceased at
least 6 weeks before start of the study. Eligible patients were aged
at least 18 years, with an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1 and adequate liver function,
deﬁned by total bilirubin1.5 the upper limit of normal (ULN;
except for documented Gilbert's disease), ASAT and ALAT2.5
ULN (or5ULN if livermetastases are present). Patients with a
medical history of seizures or predisposition to seizures were
excluded. Medication or herbal supplements which may interact
with either cabazitaxel or enzalutamide, for example, by induc-
tion or inhibition of CYP3A4, CYP2C8, CYP2C9, or CYP2C19,
were prohibited during this trial.
Study design
Patients received three consecutive cycles of cabazitaxel as a
1-hour infusion of 25 mg/m2 once every 3 weeks. Dose
modiﬁcations of cabazitaxel were allowed to a minimal dose of
12.5 mg/m2 (50% of the registered dose). Premedication con-
sisted of intravenously given dexamethasone (10 mg), followed
by granisetron 1 mg. Oral prednisone, at a dose of 5 mg twice
daily, was taken for as long as cabazitaxel treatment continued. At
day 7 after the ﬁrst cabazitaxel cycle within the study, a daily dose
of 160 mg enzalutamide (four capsules of 40 mg, orally) was
addeduntil eight (plus/minusone) days after the third cabazitaxel
cycle. So, enzalutamide was cotreated for a total of 6 weeks.
Enzalutamide administration was at 10.00 AM, without permis-
sion of dose interruptions or modiﬁcations. Patient compliance
was assessed through a patient diary. Using this cross-over design
all patients were their own control, making enzalutamide come-
dication the only structural varying factor. See Fig. 1 for a sim-
pliﬁed scheme of the study design.
Pharmacokinetic assessments
Plasma samples for cabazitaxel pharmacokinetic assessments
were obtained at cycle 1 (before initiation of enzalutamide
dosing), cycle 2 and at cycle 3, when steady state levels of
enzalutamide have been reached. Blood samples (4 mL) were
withdrawn on the ﬁrst day of each cabazitaxel cycle, at different
time-points (pre-infusion and at 0.5, 0.92, 1.08, 1.25, 1.5, 2, 3, 5,
7, 11–13, 24, and 192 hours after the start of cabazitaxel).
Measurement of plasma concentrations of cabazitaxel was per-
formed using a validated liquid chromatography with tandem
mass spectrometry methods (UP-MS/MS; refs. 19). We used
noncompartmental analysis (Phoenix version 6.1; Pharsight) and
estimated the residual AUC by a linear pharmacokinetic curve
from the latest measurable pharmacokinetic point. The last phar-
macokinetic sample was taken at 192 hours, which corresponds
with the regular control at the outpatient clinic at 1 week after
cabazitaxel infusion. Pharmacokinetic parameters determined
Translational Relevance
Preclinical data suggest enhanced efﬁcacy of cabazitaxel
when combined with hormonal therapies for metastatic cas-
tration-resistant prostate cancer (mCRPC). Clinical studies on
combining taxanes, i.e., docetaxel and cabazitaxel, and AR-
targeted agents, that is, enzalutamide and abiraterone, are
ongoing. It is important to be aware of potential drug–drug
interactions between these agents, especially since enzaluta-
mide is known to be a strong CYP3A4 inducer and taxanes are
metabolized by this enzyme. We performed a pharmacoki-
netic study to identify the inﬂuence of enzalutamide on
cabazitaxel concentrations in mCRPC patients. We found a
potential clinically relevant reduction in cabazitaxel concen-
tration (>20%) when combined with enzalutamide. None-
theless, the combination was safe and well-tolerated. More-
over, PSA response levels were higher than expected in this
heavily pretreated patient population. Studies with this drug
combination are warranted, but investigators need to be aware
of the current ﬁndings.
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included cabazitaxel exposure [expressed as dose-corrected area
under the plasma concentration time curves from time zero to
inﬁnity (AUC0–inf)].When cabazitaxel concentrations were below
the limit of detection at this point, we used the 24-hour sampling
point as latest pharmacokinetic sample, and therefore the dose
corrected AUC0-24h as primary outcome measurement. Other
pharmacokinetic parameters included were the maximum drug
concentration (Cmax), and its half-life (t1/2).
PSA assessments
Although not speciﬁed per protocol, serum PSA levels were
determined at study baseline and before start of each cycle.
Exploratory analyses were performed to identify proportion of
patients with 50% decline of PSA from study start compared to
the end of the treatment period.
Statistical analysis
To take into account dose-reduced cabazitaxel cycles, all
measured concentrations were dose-corrected to a dose of 25
mg/m2 by the formula AUC(25/dose given in that cycle).
Before analyzing the dose-corrected AUC and maximum caba-
zitaxel concentrations (Cmax), a natural log transformation of
these data was performed to take into account possible devia-
tions from normality. The (log) dose-corrected AUC of caba-
zitaxel without enzalutamide (AUC Cycle 1) was compared
with the (log) dose-corrected AUC of cabazitaxel with enzalu-
tamide (AUC Cycle 3), using a paired t-test. In addition, as a
secondary endpoint, the same test was used to compare (log)
dose-corrected AUC of cycle 1 to cycle 2, the (log) maximum
cabazitaxel concentration (Cmax) in cycle 1 to cycle 3, and the
same for the half-life (t1/2) of cabazitaxel. The mean differences
and 95% CIs for the differences were exponentiated to provide
point estimates of the ratio of geometric means and 95%CIs for
these ratios, which can be interpreted as relative differences in
percentages. The study required an estimated sample size of 14
evaluable patients to detect a clinical relevant difference in AUC
with 80% power and a two-sided signiﬁcance level of 0.05. IBM
SPSS Statistics 21 was used for all analyses.
Results
Patient characteristics and pharmacokinetic parameters
Baseline characteristics are available for all 14 patients and are
shown in Table 1. All patients were chemically castrated and used
androgen-deprivation therapy throughout the whole study peri-
od. Cabazitaxel pharmacokinetic parameters are shown in Table
2. We aimed to identify the AUC0–inf of cabazitaxel by collecting
pharmacokinetic samples up to 192 hours. However, in most
cases the concentration of cabazitaxel was below the detection
limit (LLQ) in the 192-hour pharmacokinetic samples. As a result
the residual AUC was >20% of the total AUC, which is not
acceptable according to the general pharmacokinetic assump-
tions. Therefore, we had to decide to limit our AUC calculation
up to the 24-hour sample (AUC0–24h).
The geometricmean exposurewas 22%(95%CI, 9%–34%, P¼
0.005) lower in the third cycle (cabazitaxel combined with
Table 1. Patient characteristics
Characteristic Value no. (%)
Evaluable patients (n) 14 (100)




Liver function baseline, mean  SD
Bilirubine (mmol/L) 5.4  2.1
ASAT (U/L) 24.6  9.9










Abbreviations: n, number; WHO, World Health Organization.
aExperimental includedparticipation in phase I and II clinical trial with avariety of
agents: TAS-119, ARN-509, dendritic cell therapy.
Figure 1.
Study design. The study included three consecutive courses of cabazitaxel, and 1 week after the ﬁrst cabazitaxel cycle enzalutamide was added for a period of 6
weeks.
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enzalutamide: AUC0–24h of 181 ngh/mL; 95% CI, 150–219
ngh/mL) compared to the ﬁrst cycle (cabazitaxel monotherapy:
AUC0–24h of 234 ngh/mL; 95% CI, 209–261 ngh/mL). Inter-
estingly, this decrease was already observed during cycle 2 (AUC0–
24h of 182 ngh/mL; 95% CI, 157–211 ngh/mL; relative differ-
ence ¼ 22%; 95% CI, 13% to 31%; P < 0.001) despite the
shorter period of the drug–drug combination during that cycle. In
addition, the variation in pharmacokinetic effects, as expressed by
the coefﬁcient of variation (CV%), was higher in the third cycle
than in cycle 1 and cycle 2 in the study, respectively 34%, 19%, and
26%, see Fig. 2. As secondary endpoints other pharmacokinetic
endpoints; maximum concentration (Cmax) of cabazitaxel and
half-life (t1/2) of cabazitaxel were measured, and compared
between cycle 1 and cycle 3. The maximum concentration of
cabazitaxel in the ﬁrst cycle (Cmax 138 ng/mL; 95% CI, 111–171
ng/mL) was signiﬁcantly higher than in the third cycle (Cmax 96
ng/mL; 95% CI, 86–108 ng/mL; relative difference, 30%; 95%
CI,42 to16%; P¼ 0.001). There was no difference in half-life
of cabazitaxel between both cycles (cycle 1: t1/2 ¼ 22 hours; 95%
CI, 14–33 hours vs. cycle 3: t1/2¼ 18 hours; 95%CI, 12–27 hours;
relative difference¼18%; 95%CI,59% to64%; P¼ 0.552).
Toxicity and PSA response
There were no unexpected serious adverse events (SAE) during
combined treatment with these drugs. A total of four SAEs were
generally related to cabazitaxel treatment (monotherapy), includ-
ing neutropenic fever (two times), deep venous thrombosis, and
hypertension. Hypertension (grade 3) occurred during the third
cycle, although this patientwas already knownwithhypertension.
The deterioration of the blood pressure may be attributed to
enzalutamide use as well. Four of six (67%) grade 3–4 adverse
events occurred during cabazitaxel monotherapy, whereas the
other two adverse events happened during the combination
therapy of cabazitaxel and enzalutamide, indicating an overall
well-tolerated combination strategy.
Because PSA response was not speciﬁed per protocol, we
analyzed response rates in an explorative way. Because baseline
PSA was missing for one patient, PSA analyses were performed in
13 of 14 patients. PSA responses of 50%ormore were observed in
8 (62%) of the 13 patients at completion of the three consecutive
cycles of cabazitaxel in the study, which we regarded as high given
the extensive prior treatment in this typical patient cohort (Fig. 3).
Five of the PSA responders had prior treatment with an AR-agent,
andboth cabazitaxel pre-treated patients had a>50%PSAdecline.
Discussion
In this pharmacokinetic cross-over study in patients with
mCRPC treated with cabazitaxel, we evaluated the difference in
exposure (AUC0–24h) of cabazitaxel when administered with or
without enzalutamide. Our study showed a signiﬁcant and poten-
tially clinically important reduction (22%) in cabazitaxel expo-
sure by simultaneous treatment with enzalutamide.
As mentioned, enzalutamide is classiﬁed as a strong inducer of
CYP3A4 enzyme (17), and all taxanes, including cabazitaxel, are
metabolized primarily by this enzyme. Therefore, a drug–drug
interaction was expected a priori, although the magnitude of that
interaction was uncertain. In this study, the inductive effects of
enzalutamide on cabazitaxel exposure is relatively high and
results in a clinically relevant interaction between these agents.
In contrast, Morris and colleagues (18) found a moderate 12%
reduction of docetaxel concentration (AUCinf) with concomitant
enzalutamide use. The substantial difference between the iden-
tiﬁed percentages of enzalutamide related drug induction in the
study ofMorris and colleagues (18) and our cohort may be due to
the different taxanes that were used. Although our primary end-
point was to compare cabazitaxel study cycle 1 to cabazitaxel
study cycle 3, we already saw comparable geomean cabazitaxel
AUC0–24h decreases during cabazitaxel study cycle 2, following 14
days of treatment with enzalutamide. Although the steady state
levels of enzalutamide are reached after 4 weeks, the inducing
effect on CYP3A4 is probably complete after 2 weeks. This
observation is consistent with prior observations that induction
of CYP enzymes is complete within 9–14 days after start of
treatment with strong CYP inducers (20). Nonetheless, study
cycle 3 was not similar to study cycle 2: the interpatient variability
was substantially higher in the third cycle, as several patients had
higher cabazitaxel concentrations in that cycle than in cycle 2.
Contrarily, other patients had a further decrease in cabazitaxel
exposure in the third cycle (Fig. 2). The interpatient variability of
cabazitaxel is moderate with 24% (10). In this study, it appears
that interpatient variability (%CV) increases when cabazitaxel is
combined with enzalutamide and even further in consecutive
Table 2. Cabazitaxel pharmacokinetics
Cabazitaxel PK parameters C1 (caba) C2 (cabaþenza) C3 (caba þ enza) Difference C3/C1 % (95% CI) Pa
AUC0–24h; ngh/mL (CV%) 234 (19) 182 (26) 181 (34) 22 (9 till 34) 0.005
Cmax; ng/mL (CV%) 138 (39) 96 (49) 96 (20) 30 (42 till 16) 0.001
t1/2; h (CV%) 22 (87) 14 (41) 18 (79) 18 (59 till 64) 0.552
Abbreviations: AUC0–24h, area under the curve for 24 hours; C1/2/3, cycle 1/2/3; caba, cabazitaxel; CI, conﬁdence Interval, expressed as geomean; Cmax, max
concentration, expressed as geomean; CV%, coefﬁcient of variation; enza, enzalutamide; PK, pharmacokinetics; t1/2, half-life, expressed as geomean.
aComparison between cycle 1 and cycle 3.
Figure 2.
Individual dose-corrected cabazitaxel AUC0–24h. Each line refers to one patient.
The dose-corrected AUC0–24h of cabazitaxel (y-axis) is measured per cycle
(x-axis), and AUC values for individual patients are connected between the
cycles.
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cycles. We cannot provide a clear explanation for this phenom-
enon. This increased variation was not dependent on occurrence
of hepatotoxicity, comedication, or number of cabazitaxel cycles
preceding the start of this study. Also patient compliance to daily
take oral enzalutamide did not differ during the cycles, based on
notes in patient diaries. Moreover, medication or herbal supple-
ments that could interact with enzalutamide were prohibited per
protocol, so the risk of interpatient variation in pharmacokinetics
of enzalutamide, with potential impact on pharmacokinetics of
cabazitaxel, is brought back to the minimum. However, enzalu-
tamide concentrationswerenotmeasured,which is a limitationof
our study.
Recently, the results of the `PROSELICA' study have become
available. PROSELICA was a postmarketing study, mandated by
the FDA, to investigate if a 20 mg/m2 three-weekly dose of
cabazitaxel is noninferior to the standard dose of 25 mg/m2
(21). The PROSELICA study showed anoninferior overall survival
outcomewith the 20mg/m2 dose. As expected the lower dose was
also associated with a notably favorable adverse event proﬁle.
Although to date the dose in the label has not been changed, in
clinical practice the use of the 20 mg/m2 dose is being adopted
widely, both in the United States and in Europe. If indeed such a
lower dose of cabazitaxel is applied, an additional reduction of
22% in cabazitaxel exposure by enzalutamide may result in
subtherapeutical cabazitaxel concentrations.
Interestingly, the PSA response, which was studied explorative-
ly, was higher in this study than the response rate reported in the
TROPIC trial, which was the registration trial for cabazitaxel
treatment (62% vs. 39%; refs. 22, 23). The higher PSA response
is encouraging, because most of our patients had received prior
AR-targeted therapy, several had previously been treated with
cabazitaxel, and several had been on clinical phase I and II studies
with a variety of drugs, rendering the fourth or even ﬁfth line
treatment. Moreover, in our cohort the cabazitaxel concentration
was reduced with a mean of 22% for two cycles due to the drug–
drug interactionwith enzalutamide. This implies that the additive
effect of the drug–drug combination on PSA response is prom-
ising, despite the inductive effects of enzalutamide on cabazitaxel
pharmacokinetics. Still, our response rates should be interpreted
with caution due to the exploratory design of the analysis, the
small sample size, and the limited study period.
Furthermore, the combination treatment was very well toler-
ated considering the low incidence and severity of adverse events,
although our results should be seen in perspective given the short
treatment period and the prior cabazitaxel cycles that were
allowed. In a recent study by Massard and colleagues on the
combination of cabazitaxel and abiraterone, also a lower inci-
dence of grade 3 neutropenia was reported than in the TROPIC
trial (56%). This lower incidence of neutropenia did not result in
less (marker) efﬁcacy, as PSA levels dropped in 46% patients (4).
In conclusion, our study shows a signiﬁcant and clinically
relevant reduction in cabazitaxel exposure when combined with
enzalutamide, most probably due to CYP3A4 induction by enza-
lutamide. Prospective clinical studies with this promising com-
bination are warranted, but investigators need to be aware of the
observed drug–drug interaction.
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